fulvestrant has been researched along with er-086526 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shiroiwa, T | 1 |
| Kanomata, N; Kurebayashi, J; Moriya, T; Shimo, T; Yamashita, T | 1 |
| Chae, YS; Jeong, JH; Jung, JH; Lee, DH; Lee, IH; Lee, J; Lee, SJ; Park, HY | 1 |
| Asano, M; France, D; Funahashi, Y; Nakagawa, T; Niwa, Y; Semba, T | 1 |
4 other study(ies) available for fulvestrant and er-086526
| Article | Year |
|---|---|
[Economic evaluation of treatment on breast cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Costs and Cost Analysis; Estradiol; Female; Fulvestrant; Furans; Humans; Ketones; Trastuzumab | 2012 |
Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Furans; Humans; Ketones; Neoplastic Stem Cells; Tamoxifen | 2016 |
Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fulvestrant; Furans; Humans; Ketones; MCF-7 Cells; Tamoxifen; Trastuzumab | 2019 |
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Furans; Gene Expression Regulation, Neoplastic; Humans; Ketones; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2020 |